KLP Kapitalforvaltning AS Invests $15.28 Million in United Therapeutics Co. (NASDAQ:UTHR)

KLP Kapitalforvaltning AS acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 43,300 shares of the biotechnology company's stock, valued at approximately $15,278,000. KLP Kapitalforvaltning AS owned 0.10% of United Therapeutics as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Wealthfront Advisers LLC boosted its holdings in United Therapeutics by 2,090,573.5% during the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the period. Geode Capital Management LLC boosted its holdings in United Therapeutics by 4.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock valued at $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC boosted its holdings in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after acquiring an additional 314,004 shares during the period. Pacer Advisors Inc. boosted its holdings in United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock valued at $210,869,000 after acquiring an additional 30,931 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock valued at $164,978,000 after acquiring an additional 50,409 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $312.99 on Monday. The stock has a market capitalization of $14.06 billion, a P/E ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82. The business has a fifty day moving average price of $345.10 and a 200 day moving average price of $357.05.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business posted $4.36 EPS. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $939,625.74. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 80,255 shares of company stock worth $28,995,021 in the last three months. 11.90% of the stock is owned by insiders.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent analyst reports. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.